Anticipated $1.77 EPS for Celgene Corporation (CELG) as of May, 4

May 3, 2018 - By Anthony Rauscher

Celgene Corporation (NASDAQ:CELG) Corporate Logo
During Q4 2017 the big money sentiment decreased to 0.83. That’s change of 0.34, from 2017Q3’s 1.17. 156 investors sold all, 478 reduced holdings as Celgene Corporation ratio dropped. 411 increased holdings while 118 funds took holdings. Funds hold 561.38 million shares thus 7.06% less from 2017Q3’s 603.99 million shares.
First Allied Advisory accumulated 0.32% or 76,480 shs. Van Cleef Asset Managementinc reported 11,925 shs. Symphony Asset Management Ltd Llc holds 0.15% of its capital in Celgene Corporation (NASDAQ:CELG) for 14,167 shs. Clarivest Asset Limited Liability reported 256,813 shs. Waldron L P holds 0.09% of its capital in Celgene Corporation (NASDAQ:CELG) for 3,498 shs. Tokio Marine Asset Company stated it has 106,447 shs. Telemus Capital holds 0.21% or 26,123 shs in its capital. Meridian Counsel holds 0.17% or 2,984 shs in its capital. Gradient Limited Liability, Minnesota-based fund reported 85 shs. American Money Mgmt Ltd Company has invested 1% in Celgene Corporation (NASDAQ:CELG). Massmutual Trust Fsb Adv has 0.03% invested in Celgene Corporation (NASDAQ:CELG). Fred Alger Mgmt stated it has 1.40M shs. Amalgamated National Bank reported 0.29% stake. Monetary Mgmt, Missouri-based fund reported 43,540 shs. Cubist Systematic Strategies Ltd Llc holds 0.11% or 20,241 shs.

Celgene Corporation had 3 selling transactions and 1 buy since February 8, 2018. This’s net activity of $3.58 million. KAPLAN GILLA had sold 18,500 shs worth $1.77M. Shares for $1.26M were sold by MARIO ERNEST on Friday, February 23. $299,594 worth of stock was bought by Alles Mark J on Thursday, February 8.

Celgene Corporation (NASDAQ:CELG)’s earnings report is anticipated by WallStreet on May, 4, according to Faxor. Analysts have anticipation on stock’s EPS of $1.77. That’s up 15.69 % from last year’s $1.53 EPS. If $1.77 is reported, CELG’s profit will hit $1.33B for 12.27 P/E. Last quarter $1.87 EPS was reported. Analysts predicts -5.35 % negative EPS growth this quarter. The stock decreased 1.17% or $1.03 during the last trading session, reaching $86.9.Celgene Corporation has volume of 3.92 million shares. Since May 3, 2017 CELG has declined 31.28% and is downtrending. CELG underperformed by 42.83% the S&P 500.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

In total 20 analysts cover Celgene (NASDAQ:CELG). “Buy” rating has 13, “Sell” are 0, while 7 are “Hold”. (NASDAQ:CELG) has 65% bullish analysts. With $155 highest and $92.0 lowest price target, Celgene has $122.76 average price target or 41.27% above the current ($86.9) price. 33 are the (NASDAQ:CELG)’s ratings reports on May 3, 2018 according to StockzIntelligence Inc. On Thursday, January 25 Guggenheim maintained Celgene Corporation (NASDAQ:CELG) rating. Guggenheim has “Buy” rating and $144.0 target. The stock rating was maintained by RBC Capital Markets with “Buy” on Wednesday, April 4. On Wednesday, February 28 the stock of Celgene Corporation (NASDAQ:CELG) earned “Hold” rating by Robert W. Baird. On Thursday, January 18 the firm earned “Hold” rating by Piper Jaffray. On Friday, January 5 the stock of Celgene Corporation (NASDAQ:CELG) earned “Hold” rating by Bank of America. The company rating was maintained by Canaccord Genuity on Tuesday, January 23. On Wednesday, February 28 the company was maintained by Stifel Nicolaus. In Friday, April 13 report Morgan Stanley maintained the stock with “Equal-Weight” rating. In Wednesday, December 27 report Bernstein downgraded the stock to “Market Perform” rating. On Friday, November 17 the company was maintained by BMO Capital Markets.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide.The company has $65.36 billion market cap. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.The P/E ratio is 23.87. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

Celgene Corporation (NASDAQ:CELG) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.